bpc 157 fda not approved warning panel is reviewing if 7 peptides should be made more accessible, an RFK Jr. priority An FDA advisory panel voted

Any use should be medically supervised, with compliance and safety front and center

Once more than 50 amino acids combine into a longer entity, we no longer speak of peptides, but of polypeptides and extensive proteins

Overall, this experience was expensive, unsatisfactory and ultimately useless

For broader context on multi-compound research designs, see our peptide research stacks overview

Microdosing GLP-1/GIP therapies may help: Improve glycemic control, stable blood glucose levels, and blood pressure support Reduction in visceral fat and waist circumference Potential improvements in lipid profiles Reduce systemic inflammation markers associated with cardiometabolic disease Glycine amino acid that supports protein synthesis, endothelial function, and insulin sensitivity Reduce cardiovascular risk factors such as insulin resistance and central adiposity Whats Included Monthly compounded tirzepatide + glycine (Up to 3mg/week) or 2ml tirzepatide with B12 every 2 months with labs Personalized microdosing protocol Ongoing provider oversight with labs every six months This is not an FDA-approved microdosing regimen